| Compound | Retatrutide |
| Strength | 10mg, 20mg, 30mg, 40mg |
| Size_value | 10, 20, 30, 40 |
| Size_unit | mg |
| Vial_count | 1 |
| Purity_claim | ≥99% |
| Format | lyophilized vial |
10mg
| Quantity | Discount | Price |
| 5 – 8 | 5% | $94.05 |
| 9 + | 10% | $89.10 |
$149.00 – $399.00Price range: $149.00 through $399.00
Retatrutide (LY3437943) is a novel synthetic peptide and the first “triple hormone receptor agonist” to enter advanced research phases. It builds upon the mechanisms of earlier GLP-1 (Semaglutide) and dual GLP-1/GIP (Tirzepatide) agonists by adding a third target: Glucagon.
Researchers categorize Retatrutide as a “GGG” agonist because it simultaneously activates the receptors for GLP-1 (Glucagon-like Peptide-1), GIP (Glucose-dependent Insulinotropic Polypeptide), and GCGR (Glucagon Receptor). This unique triple-action mechanism is investigated for its potential to produce unprecedented efficacy in metabolic regulation. While GLP-1 and GIP work synergistically to improve insulin secretion and suppress appetite, the addition of Glucagon agonism is hypothesized to increase energy expenditure (thermogenesis) and enhance lipid metabolism in the liver, theoretically accelerating the reduction of adipose tissue beyond what is possible with dual agonists.
Key Research Applications
Maximal Efficacy Weight Regulation: Retatrutide is currently the “ceiling” of weight loss research. Phase 2 clinical data (published in The New England Journal of Medicine) observed mean body weight reductions of up to 24.2% in test subjects over 48 weeks—outperforming all previous generations of incretin mimetics.
Hepatic Health (Fatty Liver): Due to the specific inclusion of the Glucagon receptor (which promotes hepatic lipid clearance), Retatrutide is a primary subject of investigation for MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease). Research indicates it may rapidly mobilize liver fat, improving hepatic markers faster than GLP-1 mono-therapies.
Energy Expenditure: The “Glucagon component” is researched for its ability to increase resting metabolic rate. Unlike Tirzepatide which primarily lowers caloric intake, Retatrutide is investigated for both lowering intake and increasing output.
⚠️ FOR RESEARCH PURPOSES ONLY This product is intended for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic use. Handle with care and adhere to all laboratory safety protocols.
| Compound | Retatrutide |
|---|---|
| Strength | 10mg, 20mg, 30mg, 40mg |
| Size_value | 10, 20, 30, 40 |
| Size_unit | mg |
| Vial_count | 1 |
| Purity_claim | ≥99% |
| Format | lyophilized vial |
Reviews
There are no reviews yet.